Polysaccharide-Based Nanocarriers for Oral Delivery of Insulin in Diabetes

2020 ◽  
pp. 183-193
Author(s):  
Awanish Kumar ◽  
Shraddha Gupta ◽  
Dhakshinamoorthy Vasanth
Keyword(s):  
Oral Delivery

N-Trimethyl chitosan-coated multivesicular liposomes for oxymatrine oral delivery

2009 ◽  
pp. 090526005142032-9 ◽  
Author(s):  
Jinna Cao ◽  
Jukui Sun ◽  
Xiaoyu Wang ◽  
Xinran Li ◽  
Yingjie Deng
Keyword(s):  
Oral Delivery ◽  
Trimethyl Chitosan

Solid lipid nanoparticles for oral delivery of curcumin

Planta Medica ◽  
2013 ◽  
Vol 79 (13) ◽  
Author(s):  
C Righeschi ◽  
M Bergonzi ◽  
B Isacchi ◽  
A Bilia
Keyword(s):  
Solid Lipid Nanoparticles ◽  
Oral Delivery ◽  
Lipid Nanoparticles ◽  
Solid Lipid

FORMULATION AND EVALUATION OF INDOMETHACIN LOADED NANOSPONGES FOR ORAL DELIVERY

2018 ◽  
Vol 75 (5) ◽  
pp. 1201-1213
Author(s):  
Nasir Abbas ◽  
Komal Sarwar ◽  
Muhammad Irfan ◽  
Amjad Hussain ◽  
Rabia Mehmood ◽  
...  
Keyword(s):  
Oral Delivery

Submicron Emulsions and Their Applications in Oral Delivery

2016 ◽  
Vol 33 (3) ◽  
pp. 265-308 ◽  
Author(s):  
Veenu Mundada ◽  
Mitali Patel ◽  
Krutika Sawant
Keyword(s):  
Oral Delivery ◽  
Submicron Emulsions

Microsponges: An Overview

2017 ◽  
Vol 4 (4) ◽  
Author(s):  
Hamid Hussain ◽  
Divya Juyal ◽  
Archana Dhyani
Keyword(s):  
Controlled Release ◽  
Delivery System ◽  
Oral Delivery ◽  
Active Agent ◽  
Topical Delivery ◽  
Water Soluble ◽  
Wide Range ◽  
Porous Beads

Microsponge and Nanosponge delivery System was originally developed for topical delivery of drugs can also be used for controlled oral delivery of drugs using water soluble and bioerodible polymers. Microsponge delivery system (MDS) can entrap wide range of drugs and then release them onto the skin over a time by difussion mechanism to the skin. It is a unique technology for the controlled release of topical agents and consists of nano or micro porous beads loaded with active agent and also use for oral delivery of drugs using bioerodible polymers.

Pharmacokinetic peculiarities of drugs used in the form of rapidly dispersible tablets (oral delivery system)

2020 ◽  
pp. 7-24
Author(s):  
Zhanna Kozlova ◽  
Ivan Krasnyuk ◽  
Yuliya Lebedeva ◽  
Ekaterina Odintsova
Keyword(s):  
Oral Mucosa ◽  
Oral Delivery ◽  
Chemical Properties ◽  
Rapid Onset ◽  
Systemic Circulation ◽  
Systemic Delivery ◽  
Onset Of Action ◽  
Mucosal Drug Delivery ◽  
Physical And Chemical ◽  
Pass Metabolism

Oral mucosal drug delivery is an alternative method of systemic delivery with several advantages over both injectable and enteral methods. Drugs that are absorbed through the oral mucosa directly enter the systemic circulation, passing through the gastrointestinal tract and first-pass metabolism in the liver due to oral mucosa being highly vascularised. This results in rapid onset of action for some drugs because of a more comfortable and convenient way of delivery than the intravenous one. But not all drugs can be administered through the oral mucosa due to characteristics of the oral mucosa and physical and chemical properties of the drug.

Fenofibrate Solid Dispersion for Improving Oral Bioavailability: Preparation, and Characterization and in vivo Evaluation

2020 ◽  
Vol 13 (5) ◽  
pp. 5102-5109
Author(s):  
Venu Madhav K ◽  
Somnath De ◽  
Chandra Shekar Bonagiri ◽  
Sridhar Babu Gummadi
Keyword(s):  
Oral Bioavailability ◽  
Oral Delivery ◽  
Solid Dispersions ◽  
In Vitro Release ◽  
Aqueous Solubility ◽  
Water Soluble ◽  
Scanning Calorimetry ◽  
In Vivo Evaluation

Fenofibrate (FN) is used in the treatment of hypercholesterolemia. It shows poor dissolution and poor oral bioavailability after oral administration due to high liphophilicity and low aqueous solubility. Hence, solid dispersions (SDs) of FN (FN-SDs) were develop that might enhance the dissolution and subsequently oral bioavailability. FN-SDs were prepared by solvent casting method using different carriers (PEG 4000, PEG 6000, β cyclodextrin and HP β cyclodextrin) in different proportions (0.25%, 0.5%, 0.75% and 1% w/v). FN-SDs were evaluated solubility, assay and in vitro release studies for the optimization of SD formulation. Differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD) and scanning electron microscopy (SEM) analysis was performed for crystalline and morphology analysis, respectively. Further, optimized FN-SD formulation evaluated for pharmacokinetic performance in Wistar rats, in vivo in comparison with FN suspension.  From the results, FN-SD3 and FN-SD6 have showed 102.9 ±1.3% and 105.5±3.1% drug release, respectively in 2 h. DSC and PXRD studies revealed that conversion of crystalline to amorphous nature of FN from FT-SD formulation. SEM studies revealed the change in the orientation of FN when incorporated in SDs. The oral bioavailability FN-SD3 and FN-SD6 formulations exhibited 2.5-folds and 3.1-folds improvement when compared to FN suspension as control. Overall, SD of FN could be considered as an alternative dosage form for the enhancement of oral delivery of poorly water-soluble FN.

Sign in / Sign up

Export Citation Format

Share Document